Mary Kay Inc. Names Wendy Wang President for the Asia Pacific Region
Global beauty brand Mary Kay Inc., a leading corporate advocate of women’s entrepreneurship and empowerment, with its global headquarters in Addison, Texas, U.S.A, recently announced the appointment of Wendy Wang as President of its Asia Pacific Region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310005138/en/
Wendy Wang, President of Mary Kay’s Asia Pacific Region (Photo: Mary Kay Inc.)
In her new role, Wang will provide strategic vision and leadership while working to create growth for the Company in the Asia Pacific region and beyond. Wang joined Mary Kay’s Corporate Legal Department in 2002 as Counsel for the Asia Pacific region. Shortly thereafter, she began a multi-year assignment in China. Upon her return to the global corporate headquarters in 2012, she was promoted to the position of Vice President and Associate General Counsel where she was responsible for legal work and compliance in all four regions. In 2019, Wang returned to China for a new assignment and was promoted to the position of Chief Commercial Officer for the Asia Pacific Region in 2020. In this role, she developed and drove the implementation of commercial strategies, and lead the Asia Pacific regional team in support of sales, marketing, business technology and operations, preparing her to take on the challenge of the Region President responsibilities.
“We want to congratulate Wendy as she transitions into her new role as President of Mary Kay Asia Pacific,” said David Holl, Mary Kay Chairman and Chief Executive Officer. “Wendy is passionate for the Mary Kay independent sales force and is a proven leader within Mary Kay. During her tenure, she has tirelessly built a strong and talented legal team that created a culture of compliance and compassion for China and the entire Asia Pacific Region. We are thrilled to welcome her as a member of the executive committee as we build on our efforts to enrich women’s lives around the globe.”
A graduate of The University of Texas at Austin, Wang earned her law degree as well as an undergraduate degree in Economics. She has received numerous honors and accolades including her recognition in 2017 by D CEO magazine as ‘Outstanding Deputy General Counsel/Associate General’ and the Greater Dallas Asian American Chamber of Commerce ‘Corporate Executive Diversity’ award.
“I am committed to empowering women and their families in the Asia Pacific region,” says Wang. “Supporting Mary Kay’s independent sales force is my greatest honor and always brings me hope, love and confidence in our future. We are a people business with a mission to enrich women’s lives and a vision to empower the Independent Beauty Consultant. My team and I are committed to delivering the very best business opportunity, building upon the values Mary Kay upholds as cornerstones of our corporate culture and mission.”
The promotion of Wang is the latest in Mary Kay Inc.’s decades-long commitment to empowering women to serve in leadership positions around the globe. Mary Kay is a company built by women for women, and that core value is reflected in Mary Kay’s global workforce gender diversity data (as of March 2021):
- 61% of Mary Kay’s global workforce is female
- 59% of Directors and above are female
- 54% of Global Vice Presidents and above are female
- Over 50% of Mary Kay’s global executive team is female
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company nearly 60 years ago with three goals: develop a rewarding opportunity for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay Inc. is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances which are sold exclusively by Mary Kay independent beauty consultants.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005138/en/
Contact information
Mary Kay Inc. Corporate Communications
Marykay.com/newsroom
(+1) 972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom